Remembering Mr. Sergio Marchionne
The board of directors of Philip Morris International (NYSE:PM) is deeply saddened by the passing of Mr. Sergio Marchionne, an esteemed member of the board. We offer our condolences to his family and friends in this difficult time. As one of the most respected business leaders, his creativity and passion will be etched in the hearts and minds of those who knew him. Mr. Marchionne will be remembered for the remarkable legacy that he leaves behind.
Philip Morris International media office
T: +41 (0)58 242 4500
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market17.10.2018 09:18 | Tiedote
Biogen (Nasdaq:BIIB) and Samsung Bioepis Co., Ltd. today announced the European launch of IMRALDI™ (adalimumab), a biosimilar referencing HUMIRA®. Starting today, IMRALDI™ will begin launching in major markets across Europe. The launch of IMRALDI™ marks a significant milestone for Biogen and Samsung Bioepis, as the adalimumab product is the third anti-TNF biosimilar developed by Samsung Bioepis to be commercialized by Biogen across Europe. BENEPALI™ (etanercept) and FLIXABI™ (infliximab) were approved in 2016, and have approximately 100,000 patients currently under treatment with more than 6 million doses administered across 25 and 14 countries, respectively.ii “We look forward to increasing patient access to this important medicine by leveraging our industry-leading position in the European anti-TNF market,” said Ian Henshaw, Head of Biogen’s Biosimilars Unit. “The launch of IMRALDI marks what we believe to be a landmark moment for Biogen and Samsung Bioepis and for European healthcar
Durabook Delivers World’s Toughest Semi-Rugged Computer17.10.2018 09:00 | Tiedote
Durabook, the global brand fully owned by Twinhead International Corporation, has today introduced the most durable semi-rugged computer ever created. The Durabook S14I greatly exceeds all existing devices in its class in both drop height and IP ratings. Built with 8th generation Intel® CPU and a wide selection of I/O options, the S14I is ideal for demanding working environments of public safety, government, military and field service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016006151/en/ Durabook S14I Features Class-Leading Drop Height and IP Ratings along with 8th Generation Intel CPU Power (Photo: Business Wire) “As the definition of the modern workplace expands, the line between what is office and what is field are often becoming blended” said Fred Kao, CEO of Twinhead. “So we are blending the line between what is a semi-rugged and what is a fully-rugged. Under the form factor of a traditional semi-rugged lapto
DIA Drives Debates and Solutions at the Crossroads of Healthcare17.10.2018 09:00 | Tiedote
DIA, founded as the Drug Information Association, announced three keynote speakers for the upcoming DIA Europe 2019 annual meeting: Dave deBronkart, ‘e-Patient Dave’; Hans Lehrach, Director at the Max Planck Institute for Molecular Genetics; and Kristel Van der Elst, CEO, The Global Foresight Group. The diversity of experience brought by these three leaders is reflective of the meeting mission to ensure industry, payers, patients, and regulators all have an equal voice in the debates advancing regulatory science and access to healthcare. These keynote speakers will join 300 speakers in more than 80 sessions, across seven thought leadership streams to drive collaborative answers in medicines development and access to healthcare. Highlights from sessions include Guido Rasi, Executive Director, EMA, will present first look strategies for 2021-2025 during the European Regulatory Town Hall and Niklas Hedberg, Chair EUnetHTA Executive Board, will feature case studies of Real World Evidence i
SailPoint’s Latest SaaS Release Makes Security and Compliance Accessible to All Enterprises17.10.2018 08:01 | Tiedote
SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity governance, unveiled a series of new innovations in IdentityNow, the industry’s most comprehensive SaaS identity governance platform. Enhancements have been made with an eye towards both closing security and compliance gaps and simplifying identity implementations for organizations who may not have dedicated identity teams and resources. New in IdentityNow is the Dynamic Discovery Engine, an innovation that allows users to easily and quickly create policies, access reviews, dashboards and reporting. As a result, IdentityNow customers are better able to address the mounting security and compliance challenges that all enterprises face today. “When we started our identity governance journey, a key requirement for us was the ability to automate identity processes where we could, while improving our audit and compliance track record,” said Michael Boucher, Sr. Director, Information Risk Management, FTD. “W
Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women’s Health17.10.2018 08:00 | Tiedote
Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016005907/en/ Evotec will apply its drug discovery platform to design novel and efficacious treatments in partnership with Ferring. The multi-target, multi-year collaboration aims to deliver small molecule pre-clinical development (PDC) and investigational new drug (IND) ready candidates. As part of the alliance, Evotec is eligible for undisclosed research funding and milestones. “To achieve leadership in reproductive medicine and women’s health, we are expanding beyond our historical expertise in peptides and tackling molecular targets that are best addressed using small molecule therapeutics,” said Per Fal
IWBI Launches Global Network of Advisors for WELL Portfolio16.10.2018 21:00 | Tiedote
The International WELL Building Institute™ (IWBI™) today announced the formation of a global advisory to help shape and advance the implementation of the WELL Portfolio™ Pathway pilot, a new streamlined pathway for WELL Certification™ for multiple new or existing buildings and tenant spaces in a single portfolio. WELL Portfolio, announced this past month, is being released as part of the WELL v2™ pilot, the latest iteration of the WELL Building Standard™ (WELL™). It is part of a suite of enhancements to WELL that addresses growing demand across the building industry for a program that helps owners, developers and tenants streamline and scale health and wellness upgrades to their real estate assets. The advisory includes a collection of professionals, practitioners and experts across a range of industries and sectors, each serving a one-year term. “Since we launched WELL, we’ve seen an explosion of interest from global companies to bring the same health and wellness benefits across thei
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme